Risk matrix
|
Risk |
Likelihood |
Impact |
Mitigation |
|---|---|---|---|
|
Capital-intensity J-curve (early losses) |
High |
Medium-high |
Grace period; reserves; equity-heavy mix |
|
Occupancy / referral ramp not delivered |
Medium-high |
High |
Referral partnerships; phased rollout |
|
Payer mix, tariffs & NHI uncertainty |
Medium-high |
High |
Diversified payers; outcomes-based contracting |
|
Specialist clinical-staff scarcity |
High |
High |
Recruitment, training academy, retention |
|
Multi-round capital / dilution |
Medium-high |
Medium-high |
Staged, gated rounds; DFI partners |
|
Year-1 debt-service cover below 1.0× |
High |
Medium-high |
Interest-only period; DSRA; equity buffer |
|
Regulatory / licensing (OHSC, SAHPRA) |
Medium |
High |
Clinical governance; compliance from the outset |
|
Clinical / quality / safety event |
Low-medium |
Very high |
Governance, outcomes measurement, insurance |
NoteRisk philosophy
The plan does not claim low risk; it claims a sequenced, diversified and appropriately-financed risk profile. The dominant risks are the capital-intensity J-curve, occupancy ramp, payer and workforce dynamics rather than end-demand, which is genuine and structurally supported. The roadmap gates expansion on proof, the funding structure is equity-heavy with reserves and a grace period, the payer base is diversified, workforce development is prioritised, and the returns are stress-tested on the downside.
Independent analyst findings
|
KEY FINDING Finding 1 — The healthcare-infrastructure J-curve: early-year losses Preserving revenue and EBITDA margin exactly, full depreciation on the facilities plus interest produce re-derived net losses of roughly R60m, R31m and R41m across Years 1–3, because the flagship and subsequent centres are built and financed ahead of maturing occupancy, and the Series-B build in Year 3 re-deepens the trough, before profit turns strongly positive (about R27m and R114m in Years 4–5). This is normal for a hospital-network build, is fully funded by the two equity rounds, and is disclosed rather than smoothed. |
|
|
KEY FINDING Finding 2 — Occupancy and referrals are the swing factor Revenue depends on filling beds and centres, which depends on referral relationships with tertiary hospitals and on medical-scheme and government contracting. Occupancy maturing from ~62% to ~82% is the biggest driver of the plan; a slower ramp lengthens the J-curve and strains liquidity. Underwrite a more conservative occupancy ramp, and gate expansion on demonstrated referral flow and contracts. |
|
|
KEY FINDING Finding 3 — Payer mix and NHI policy are genuine uncertainties With ~40% medical aid, ~20% government and ~15% private, the plan is exposed to medical-scheme tariffs, government-contract reliability, and NHI policy uncertainty (the Act signed in 2024, implementation on hold, a 10–15-year transition). The diversified payer base and outcomes-based contracting are the mitigants, and medical schemes are expected to continue through the transition, but payer and policy risk should be underwritten explicitly. |
|
|
KEY FINDING Finding 4 — Specialist clinical staffing is a binding constraint Paediatric rehabilitation specialists, therapists and specialist nurses are scarce in South Africa, and the sector faces broad workforce shortages. Recruitment, training (including the training academy), competitive remuneration and retention are essential, and the rollout pace is genuinely constrained by the ability to build multidisciplinary clinical teams. This is a core execution risk, not a support issue. |
|
|
KEY FINDING Finding 5 — The build is capital-hungry across multiple rounds Reaching the national network requires roughly R1.3 billion across two rounds, with Year-1 debt-service cover below 1.0× and a deep early J-curve. The structure is equity-heavy, staged and gated, and development-finance and impact lenders are natural partners, but the capital intensity, dilution and the need to raise the Series B on terms are real, and returns are exit-dependent. |
|
|
KEY FINDING Finding 6 — Regulation, licensing and clinical governance are foundational Healthcare licensing (OHSC), device and medicine regulation (SAHPRA), medical-scheme regulation (Council for Medical Schemes) and rigorous clinical governance are conditions of operation, and a clinical or safety failure would be severe. These are manageable with strong governance and outcomes measurement from the outset, which are, in any case, the foundation of payer contracting and referrals. |
Recommended conditions to funding
- An interest-only / grace period on the term debt through construction and early ramp, plus a debt-service reserve account.
- The Series B gated on demonstrated flagship occupancy, clinical outcomes and payer contracting.
- Referral-partnership agreements with tertiary hospitals and medical-scheme / government contracting as conditions precedent to each centre.
- A workforce plan, recruitment, the training academy, remuneration and retention, and healthcare licensing (OHSC) and clinical governance from the outset.
- Monthly management, occupancy, clinical-outcomes and payer reporting, and quarterly investor reporting against a defined KPI set.
Key performance indicators & investor reporting
The board, investors and lenders will monitor a concise KPI set monthly, focused on the drivers that matter most for a capital-intensive paediatric network scaling through a J-curve across two funding rounds.
|
KPI |
What it tracks |
Why it matters |
|---|---|---|
|
Occupancy & bed-days |
Capacity utilisation |
The swing factor for revenue & the J-curve |
|
Referral volume & conversion |
Hospital referral flow |
Drives occupancy |
|
Payer mix & tariff realisation |
Revenue quality |
Payer & NHI risk |
|
Clinical outcomes & readmissions |
Care quality & value |
Wins contracts & referrals |
|
Clinical vacancy & retention |
Workforce |
Binding constraint on rollout |
|
DSCR & liquidity |
Debt cover & cash |
Solvency through the ramp |